Clinical Trial

Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure

Study acronym: SGLT2-RISE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This retrospective cohort study investigates the effects of SGLT2 inhibitor therapy on erythropoiesis and its association with cardiac and renal outcomes in patients with chronic heart failure. The study will compare hematological parameters, echocardiographic measures, and clinical outcomes between patients who initiated SGLT2 inhibitor therapy and a matched control group receiving guideline-directed medical therapy alone over a 12-month follow-up period.
Trial Details
NCT Number NCT07478575
Lead Sponsor University Medical Centre Ljubljana
Collaborators: Slovenian Research Agency
Conditions Heart Failure, Anemia, Renal Insufficiency
Enrollment 85 participants
Start Date 2019-01-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-17